Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock

247wallst.com/investing/2025/10/28/neurocrine-biosciences-beats-estimates-but-wall-street-punishes-the-stock

Key Points






Neurocrine Biosciences posts standout Q3 beat as INGREZZA and CRENESSITY drive 28% product sales growth.




Neurocrine Biosciences pipeline momentum builds with Phase 3 schizophrenia trial and new MDD program progress.



The right cash back credit card…

This story appeared on 247wallst.com, 2025-10-29 00:03:08.
The Entire Business World on a Single Page. Free to Use →